NCT05054257View on ClinicalTrials.gov

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

June 1, 2025

Study Completion Date

December 12, 2025

Conditions
Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma RefractoryNon-Hodgkin's Lymphoma, Relapsed
Interventions
DRUG

Autologous CAR19 T lymphocytes

First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL

Trial Locations (1)

12800

RECRUITING

Institute of Hematology and Blood Transfusion, Czech Republic, Prague

All Listed Sponsors
lead

Institute of Hematology and Blood Transfusion, Czech Republic

OTHER

NCT05054257 - CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter